Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Change in Receivables (2020 - 2024)

Janux Therapeutics (JANX) has disclosed Change in Receivables for 5 consecutive years, with $7.0 million as the latest value for Q2 2024.

  • On a quarterly basis, Change in Receivables rose 1030.8% to $7.0 million in Q2 2024 year-over-year; TTM through Jun 2025 was $7.5 million, a 11.11% increase, with the full-year FY2021 number at -$8.0 million, down 200.0% from a year prior.
  • Change in Receivables was $7.0 million for Q2 2024 at Janux Therapeutics, up from $519000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $8.0 million in Q4 2020 to a low of -$7.6 million in Q1 2021.
  • A 5-year average of $833333.3 and a median of $500000.0 in 2022 define the central range for Change in Receivables.
  • Biggest YoY gain for Change in Receivables was 1030.8% in 2024; the steepest drop was 30.8% in 2024.
  • Janux Therapeutics' Change in Receivables stood at $8.0 million in 2020, then crashed by 104.69% to -$375000.0 in 2021, then crashed by 33.33% to -$500000.0 in 2022, then plummeted by 50.0% to -$750000.0 in 2023, then soared by 1030.8% to $7.0 million in 2024.
  • Per Business Quant, the three most recent readings for JANX's Change in Receivables are $7.0 million (Q2 2024), $519000.0 (Q1 2024), and -$750000.0 (Q2 2023).